Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0281508 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Milena Braga-Basaria und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of A…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Insulin Resistance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Androgen deprivation therapy (ADT), a cornerstone of treatment for patients with locally advanced and metastatic prostate cancer, is associated with many adverse effects, including osteoporosis, sexual dysfunction, fatigue, and vasomotor symptoms. It is also associated with loss of muscle mass and increased adiposity. This change in body composition is likely the inciting event in the development of insulin resistance, an independent risk factor for diabetes mellitus and cardiovascular disease. Although the occurrence of insulin resistance during ADT has been reported, it remains unclear whether this insulin resistance is primarily hepatic or muscular. Similarly, the mechanisms that lead to insulin resistance also remain unknown. The ADT & Metabolism Study was designed to address these knowledge gaps, as the elucidation of the predominant site of insulin resistance will allow prevention strategies and the use of targeted, tissue-specific insulin-sensitizing agents in patients undergoing ADT. This prospective, mechanistic, single-center, 24-week, observational cohort study will enroll treatment-naïve adult men with prostate cancer about to undergo surgical or medical ADT for at least 24 weeks (ADT group; n = 50) and a control group of men who had undergone radical prostatectomy and are in remission (non-ADT group, n = 25). The primary outcome is to determine the site of insulin resistance (skeletal muscle or liver) using frequent sampling oral glucose tolerance test at baseline and 12 and 24 weeks after commencement of ADT (ADT group) or after enrollment in the study (non-ADT group). Secondary outcomes will assess changes in hepatic and intramyocellular fat (using magnetic resonance spectroscopy), inflammatory markers, adipokines, free fatty acids, and changes in body composition (assessed using dual-energy x-ray absorptiometry) and their correlation with the development of insulin resistance. Exploratory outcomes will include changes in muscle performance, physical function, physical activity, vitality, and sexual drive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
- Department of Medicine, Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
- Lank Center for Genitourinary Oncology and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
- Department of Radiology, Center for Clinical Spectroscopy, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
- Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
- Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
ORCID-Profile: Alexander Lin, Daniel Habtemariam, Hussein Kafel, Shehzad Basaria
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Braga-Basaria, M., Travison, T. G., Taplin, M. E., Lin, A., Dufour, A. B., Habtemariam, D., Nguyen, P. L., Kibel, A. S., Ravi, P., Bearup, R., Kackley, H., Kafel, H., Reid, K., Storer, T., Simonson, D. C., McDonnell, M., & Basaria, S. (2023). Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0281508
Vancouver
Braga-Basaria M, Travison TG, Taplin ME, Lin A, Dufour AB, Habtemariam D, et al. Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLOS ONE. 2023. doi:10.1371/journal.pone.0281508
BibTeX
@article{BragaBasaria2023,
author = {Braga-Basaria, Milena and Travison, Thomas G and Taplin, Mary-Ellen and Lin, Alexander and Dufour, Alyssa B and Habtemariam, Daniel and Nguyen, Paul L and Kibel, Adam S and Ravi, Praful and Bearup, Richelle and Kackley, Hannah and Kafel, Hussein and Reid, Kieran and Storer, Thomas and Simonson, Donald C and McDonnell, Marie and Basaria, Shehzad},
title = {Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0281508}
}
EUVIMED